Press Release: NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A

https://ift.tt/f3IjFmz

from Sanofi - Aventis Groupe https://ift.tt/Nh9RAtc
via IFTTT

" May good health envelop you, spurring a quick recovery. .. "

from health care https://ift.tt/xFXBN86
via IFTTT https://ift.tt/T5VAQsu